|
Jul 11
|
Aegis Capital Reaffirms Buy on Atai Life Sciences N.V. (ATAI) with $8 Target
|
|
Jul 11
|
Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year?
|
|
Jul 1
|
A Promising Depression Drug Works. Psychedelics Are Back.
|
|
Jul 1
|
atai and Beckley Psytech’s psychedelic wins in Phase IIb depression trial
|
|
Jul 1
|
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday
|
|
Jul 1
|
Atai and Beckley, set to merge, reveal study success for psychedelic drug
|
|
Jul 1
|
atai Life Sciences Announces $50 Million Private Placement Financing
|
|
Jul 1
|
atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression
|
|
Jun 25
|
Are Medical Stocks Lagging atai Life Sciences (ATAI) This Year?
|
|
Jun 24
|
Maxim Group Maintains a Buy on Atai Life Sciences (ATAI) With a $6 Price Target
|
|
May 29
|
atai Life Sciences to Participate in Upcoming Investor Conferences
|
|
May 13
|
atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder
|
|
Feb 24
|
atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference
|
|
Feb 20
|
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
|
|
Feb 13
|
atai Life Sciences Announces Pricing of Public Offering of Common Shares
|
|
Feb 12
|
atai Life Sciences Announces Proposed Public Offering of Common Shares
|
|
Dec 30
|
US Penny Stocks To Consider In December 2024
|
|
Aug 7
|
atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference
|
|
Jun 26
|
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
|
|
Jun 20
|
atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
|